SEP 9, 2026 · PHASE 2 TRIAL
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
ClinicalTrials.gov
This is a clinical trial registry record describing a planned Phase 2 study with no results reported; it documents study design and biomarker strategy but carries no efficacy or safety data.
Reported
Planned enrollment40
Study phasePhase 2
Primary outcome measureObjective response rate (ORR) within 4 mont…